DNA Ginkgo Bioworks Holdings, Inc.

QT42

Latest market price

9.85

-1.36-12.13%

Overview Short InterestFilings

DNAQT42Ginkgo Bioworks Holdings, Inc.·NYSE

Overview Short InterestFilings

9.85-12.13%

Earnings

Down 12.1% — Earnings due 2026-11-05 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	—	EPS (ttm)	-5.02	Insider Own	—	Shs Outstand	67.34M	Perf Week	-1.70%

Market Cap	663.30M	Forward P/E	—	EPS next Y	-3.36	Insider Trans	-0.09%	Shs Float	49.11M	Perf Month	-20.24%

Enterprise Value	765.30M	PEG	—	EPS next Q	-0.58			Short Float	16.89%	Perf Quarter	5.12%

Income	-292.00M	P/S	5.98	EPS this Y	—			Short Ratio	4.26	Perf Half Y	-0.61%

Sales	111.00M	P/B	1.58	EPS next Y	—	ROA	-29.37%	Short Interest	8.29M	Perf YTD	18.53%

Book/sh	6.24	P/C	2.20	EPS next 5Y	—	ROE	-60.21%	52W High	18.22 -45.94%	Perf Year	-17.99%

Cash/sh	4.48	P/FCF	—	EPS past 3/5Y	—	ROIC	-31.63%	52W Low	5.37 83.43%	Perf 3Y	-83.13%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	-29.15% 17.16%	Gross Margin	80.09%	Volatility	16.88% 12.91%	Perf 5Y	-98.28%

Dividend TTM	—	EV/Sales	6.89	EPS Y/Y TTM	—	Oper. Margin	-259.86%	ATR (14)	1.37	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	4.57	Sales Y/Y TTM	-51.95%	Profit Margin	-259.96%	RSI (14)	45.67	Recom	3.00

Dividend Gr. 3/5Y	—	Current Ratio	4.57	EPS Q/Q	31.82%	SMA20	-11.81%	Beta	1.68	Target Price	5.00

Payout	0.00%	Debt/Eq	0.96	Sales Q/Q	-60.00%	SMA50	2.65%	Rel Volume	1.55	Prev Close	11.21

Employees	485	LT Debt/Eq	0.96	Earnings	Nov 05	SMA200	14.71%	Avg Volume	2.28M	Price	9.85

IPO Date	Apr 19, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.20% -16.19%	Net Debt/EBITDA	—	Volume	3,545,693	Change	-12.13%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Reiterated	Oppenheimer		$5.00
Aug-07-26	Downgrade	TD Cowen	Buy → Hold
Aug-25-25	Reiterated	BTIG	Sell	$7.00 → $9.00
Aug-23-24	Reiterated	BTIG	Sell	$6.00 → $7.00
May-15-24	Downgrade	BTIG	Neutral → Sell
May-10-24	Downgrade	William Blair	Market Perform → Underperform
Nov-15-23	Downgrade	Raymond James	Outperform → Market Perform
Nov-14-23	Downgrade	Raymond James	Outperform → Market Perform
Nov-09-23	Downgrade	BTIG	Buy → Neutral
Jun-02-23	Downgrade	Goldman Sachs	Neutral → Sell

Latest News· Times ET

Oct-29-26

Oct-29-2607:16PM

Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insightszacks.com

04:22AM

Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.fool.com

Oct-23-26

Oct-23-2605:58AM

Ginkgo Bioworks Holdings Consensus Price Target Raised 14.29% to $8.16Fintel

Oct-22-26

Oct-22-2606:00AM

Hugging Face is launching a new AI model that lets scientists 'chat with DNA'businessinsider.com

Oct-21-26

Oct-21-2607:30AM

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™globenewswire.com

Oct-20-26

Oct-20-2607:15PM

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Knowzacks.com

Oct-14-26

Oct-14-2607:16PM

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Marketzacks.com

Oct-13-26

Oct-13-2608:43AM

TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11Benzinga

Oct-09-26

Oct-09-2612:26PM

What's Going on With Ginkgo Bioworks Stock on Friday?benzinga.com

Oct-08-26

Oct-08-2608:06PM

Araceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von Nebulaprnewswire.com

04:10PM

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Programbusinesswire.com

06:39AM

Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebulaprnewswire.com

06:00AM

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loopprnewswire.com

Oct-07-26

Oct-07-2607:16PM

Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com

Oct-06-26

Oct-06-2611:01AM

Ginkgo Bioworks (NYSE:DNA) Hits New 1-Year High – Time to Buy?defenseworld.net

Company

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	111	170	227	251	—	—	—	—
Cost of Goods Sold Incl. D&A	23	32	39	54	—	—	—	—
Gross Profit	90	139	188	197	—	—	—	—
Selling, General and Administrative Excl. Other	160	183	246	385	—	—	—	—
Research and Development	215	244	424	581	—	—	—	—
Other Operating Expense	5	27	78	96	—	—	—	—
Operating Income	-291	-315	-560	-864	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-6	2	12	-28	—	—	—	—
Net Income Before Taxes	-295	-314	-548	-893	—	—	—	—
Income Taxes	-1	-1	0	0	—	—	—	—
Consolidated Net Income	-292	-313	-547	-893	—	—	—	—
Net Income From Continuing Operations	-295	-313	-547	-893	—	—	—	—
Net Income	-292	-313	-547	-893	—	—	—	—
EPS (Recurring)	-5.02	-5.64	-10.54	-18.37	—	—	—	—
EPS (Basic, Before Extraordinaries)	-5.02	-5.64	-10.54	-18.37	—	—	—	—
EPS (Diluted)	-5.02	-5.64	-10.54	-18.40	—	—	—	—
EBITDA	-242	-255	-484	-821	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	5.50	2.69	2.25	13.20	—	—	—	—
Gross Margin	81.08	81.76	82.82	78.49	—	—	—	—
Operating Margin	-262.16	-185.29	-246.70	-344.22	—	—	—	—
Net Margin	-263.06	-184.12	-240.97	-355.78	—	—	—	—
Shares Outstanding	62	55	52	49	—	—	—	—
Market Capitalization	611	457	511	3,312	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shetty Reshma P.	Director, 10% Owner, Officer	Oct 19 '26	Sale	10.14	41,172	417,608	356,329	Oct 21
Kelly Jason R	Director, Officer	Oct 19 '26	Sale	10.14	45,682	463,353	129,065	Oct 21
Canton Barry	10% Owner	Oct 19 '26	Sale	10.14	41,172	417,608	356,329	Oct 21
Coen Steven P.	Officer	Oct 19 '26	Sale	10.14	766	7,770	50,168	Oct 21
Shetty Reshma P.	Director, 10% Owner, Officer	Oct 16 '26	Option Exercise	0.00	76,462	0	476,320	Oct 21
Kelly Jason R	Director, Officer	Oct 16 '26	Option Exercise	0.00	81,484	0	174,747	Oct 21
Coen Steven P.	Officer	Oct 16 '26	Option Exercise	0.00	1,486	0	50,934	Oct 21
Canton Barry	10% Owner	Oct 16 '26	Option Exercise	0.00	76,462	0	476,320	Oct 21
Coen Steven P.	Officer	Oct 05 '26	Sale	15.00	2,403	36,045	49,448	Oct 07
HENRY CHRISTIAN O	Director	Sep 15 '26	Sale	7.08	5,000	35,405	19,310	Sep 16
Coen Steven P.	Officer	Aug 24 '26	Sale	6.98	330	2,302	51,851	Aug 25
Coen Steven P.	Officer	Aug 21 '26	Option Exercise	0.00	743	0	52,181	Aug 25
Coen Steven P.	Officer	Jul 17 '26	Sale	7.90	752	5,943	51,438	Jul 20
Coen Steven P.	Officer	Jul 16 '26	Option Exercise	0.00	1,486	0	52,190	Jul 20
Coen Steven P.	Officer	May 22 '26	Sale	8.33	307	2,559	50,704	May 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.